Literature DB >> 9973491

Position effects of variable region carbohydrate on the affinity and in vivo behavior of an anti-(1-->6) dextran antibody.

M J Coloma1, R K Trinh, A R Martinez, S L Morrison.   

Abstract

IgG is a glycoprotein with an N-linked carbohydrate structure attached to the CH2 domain of each of its heavy chains. In addition, the variable regions of IgG often contain potential N-linked carbohydrate addition sequences that frequently result in the attachment of V region carbohydrate. Nonetheless, the precise role of this V region glycan remains unclear. Studies from our laboratory have shown that a naturally occurring somatic mutant of an anti-dextran Ab that results in a carbohydrate addition site at Asn58 of the VH has carbohydrate in the complementarity-determining region 2 (CDR2) of the VH, and the presence of carbohydrate leads to an increase in affinity. However, carbohydrate attached to nearby positions within CDR2 had variable affects on affinity. In the present work we have extended these studies by adding carbohydrate addition sites close to or within all the CDRs of the same anti-dextran Ab. We find that carbohydrate is attached to all the novel addition sites, but the extent of glycosylation varies with the position of the site. In addition, we find that the position of the variable region carbohydrate influences some functional properties of the Ab, including those usually associated with the V region such as affinity for Ag as well as other characteristics typically attributed to the Fc such as half-life and organ targeting. These studies suggest that modification of variable region glycosylation provides an alternate strategy for manipulating the functional attributes of the Ab molecule and may shed light on how changes in carbohydrate structure affect protein conformation.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 9973491

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  22 in total

Review 1.  Engineering the variable region of therapeutic IgG antibodies.

Authors:  Tomoyuki Igawa; Hiroyuki Tsunoda; Taichi Kuramochi; Zenjiro Sampei; Shinya Ishii; Kunihiro Hattori
Journal:  MAbs       Date:  2011-05-01       Impact factor: 5.857

Review 2.  Structure, heterogeneity and developability assessment of therapeutic antibodies.

Authors:  Yingda Xu; Dongdong Wang; Bruce Mason; Tony Rossomando; Ning Li; Dingjiang Liu; Jason K Cheung; Wei Xu; Smita Raghava; Amit Katiyar; Christine Nowak; Tao Xiang; Diane D Dong; Joanne Sun; Alain Beck; Hongcheng Liu
Journal:  MAbs       Date:  2018-12-17       Impact factor: 5.857

3.  A study of the possible role of Fab-glycosylated IgG in tumor immunity.

Authors:  Qian Xu; Xiaodong Deng; Biying Zhang; Chanyuan Zhao; Tao Huang; Yimin Zhang; Zhiming Chen; Jiang Gu
Journal:  Cancer Immunol Immunother       Date:  2021-01-03       Impact factor: 6.968

4.  Risk-Based Comparability Assessment for Monoclonal Antibodies During Drug Development: A Clinical Pharmacology Perspective.

Authors:  Yanli Zhuang; Di Chen; Amarnath Sharma; Zhenhua Xu
Journal:  AAPS J       Date:  2018-10-15       Impact factor: 4.009

Review 5.  Mass spectrometry for the identification and analysis of highly complex glycosylation of therapeutic or pathogenic proteins.

Authors:  Yukako Ohyama; Kazuki Nakajima; Matthew B Renfrow; Jan Novak; Kazuo Takahashi
Journal:  Expert Rev Proteomics       Date:  2020-05-28       Impact factor: 3.940

Review 6.  Differential antibody glycosylation in autoimmunity: sweet biomarker or modulator of disease activity?

Authors:  Michaela Seeling; Christin Brückner; Falk Nimmerjahn
Journal:  Nat Rev Rheumatol       Date:  2017-09-14       Impact factor: 20.543

7.  Recombinant Proteins and Monoclonal Antibodies.

Authors:  Roy Jefferis
Journal:  Adv Biochem Eng Biotechnol       Date:  2021       Impact factor: 2.635

8.  Assessment of Therapeutic Antibody Developability by Combinations of In Vitro and In Silico Methods.

Authors:  Adriana-Michelle Wolf Pérez; Nikolai Lorenzen; Michele Vendruscolo; Pietro Sormanni
Journal:  Methods Mol Biol       Date:  2022

9.  Solubility evaluation of murine hybridoma antibodies.

Authors:  Stacey Spencer; Deidra Bethea; T Shantha Raju; Jill Giles-Komar; Yiqing Feng
Journal:  MAbs       Date:  2012-04-26       Impact factor: 5.857

10.  Influence of variable domain glycosylation on anti-neutrophil cytoplasmic autoantibodies and anti-glomerular basement membrane autoantibodies.

Authors:  Peng-Cheng Xu; Shen-Ju Gou; Xiao-Wei Yang; Zhao Cui; Xiao-Yu Jia; Min Chen; Ming-Hui Zhao
Journal:  BMC Immunol       Date:  2012-03-09       Impact factor: 3.615

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.